SAMPLE OF KEYNOTE SPEAKERS

This year Summit will host speakers from the world’s leading companies.
See sample of key note speakers.

Angelique
HOPKINS
Associate Director Clinical Trial Analytics
Elizabeth
ARMSTRONG
Director Clinical Management
Christine
SEYMOUR
Clinical Development Programs Director
Laura
COOKE
Director, Global Clinical Program Management & Development Design Center
Cecilia
TRAN – MUCHOWSKI
Associate Director, Clinical Operations HIV
Kevin
HUDZIAK
Clinical Innovation Lead

SELECTED CASE STUDIES

Selected Case Studies from the Agenda

Angelique HOPKINSAssociate Director Clinical Trial Analytics
Bristol-Myers Squibb

Will the struggle to meet the enrollment quotas while keeping costs under control continue?

The extremely competitive landscape in oncology clinical trials has led to more complex study designs that require larger patient accrual targets in shorter recruitment periods. The usual strategies for addressing these constraints are often costly and ineffective from an operation cost-benefit perspective. This presentation will explore the analytics behind this growing trend and explore whether this is the new industry norm.

  • Current saturation in Oncology
  • Trial timeline, increasing patient targets, decreasing recruitment rates
Christine SEYMOURClinical Development Programs Director
Ipsen

The patient engagement value model

This session will present how Ipsen has developed a patient focused clinical development model to give patients better and quicker access to a new or improved solutions of care, though a better understanding of patient perspective and improved communication on Ipsen research activities.

  • The challenges and obstacles to overcome
  • Recommendations for clinical study feasibility
  • Implementation of more patient centric protocol designs
  • Study awareness increase through digital tools
Elizabeth ARMSTRONGDirector Clinical Management
Otsuka

Retention and avoidance of missing data in a rare disease clinical trial

In 2010, the National Research Council’s Panel on handling missing data in clinical trials made 18 recommendations challenging the industry to avoid and account for missing data. With the understanding that patient’s participation in clinical trials is by voluntary consent, how can we operationalize the retention of subjects? Methods and outcomes will be covered in this presentation.

  • Trial Design Options
  • Informed Consent Options
  • Managing Assessments
  • Investigator Communications
Katie KINGPatient Recruitment Strategist
Boehringer Ingelheim

Patient first approach is a key to a successful clinical trial

In an effort to adopt patient centric practices, it has become increasingly common for key industry stakeholders to solicit patient feedback on clinical trial protocol elements, recruitment and retention strategies, and other operational aspects of clinical trial implementation. While this collaborative, data-driven approach to trial design and conduct is certainly a step in the right direction, it does not necessarily result in improvements to the clinical trial patient experience. Only by developing a thorough understanding of patient populations and by authentically honoring their needs in a patient-first approach, is industry able break down common barriers to recruitment and retention resulting in not only successful clinical trials, but also positive patient experiences.

  • Patient-first approaches
  • Patient experience
  • Patient engagement
  • Innovation